Quantcast

Daily Traders Edge

New Roche haemophilia drug prevents bleeds but questions remain

June 26
09:59 2017

New Roche haemophilia drug prevents bleeds but questions remainRoche’s investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday’s data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.


Related Articles

Newsletter Signup

Sign up for our free newsletter